[Comment] Intravesical pirarubicin after nephroureterectomy | ClinicLens
Randomised trials in rare cancers are scarce, and those that achieve adequate enrolment and methodological rigour warrant recognition. Upper tract urothelial carcinoma, which comprises only 5–10% of urothelial malignancies, presents unique challenges for trialists because of its
Medical Literature · Updated
← Back to articlesIf the embedded page does not load in your browser, open it directly.